Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2017-2022

  Karpenko, Inna ^a   Deev, Sergey ^b   Kiselev, Oleg ^c   Charushin, Valerey ^b   Rusinov, Vladimir ^b   Ulomsky, Eugeney ^b   Deeva, Ella ^c   Yanvarev, Dmitry ^a   Ivanov, Alexander ^a   Smirnova, Olga ^a   Kochetkov, Sergey ^a   Chupakhin, Oleg ^b   Kukhanova, Marina ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b INSTITUTE OF ORGANIC SYNTHESIS   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

( 2 METHYLTHIO 6 AMINO 1,2,4 TRIAZOLO[ 5,1 S] 1,2,4 TRIAZINE 7 (4I) ONE; ( 2 METHYLTHIO 6 NITRO 1,2,4 TRIAZOLO[ 5,1 C] 1,2,4 TRIAZINE 7 (4I) ONE; 1,2,4 TRIAZINE DERIVATIVE; ANTIVIRUS AGENT; RIMANTADINE; TRIAZAVIRINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD; CELL CULTURE; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DEATH; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; LIVER HOMOGENATE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; AZOLES; DISEASE MODELS, ANIMAL; DOGS; DRUG DESIGN; HEPATOCYTES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INJECTIONS, INTRAVENOUS; KIDNEY; MICE; MICE, INBRED CBA; ORTHOMYXOVIRIDAE INFECTIONS; RABBITS; STOMACH; TRIAZINES; VIRUS REPLICATION;

EID: 77951211790     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01186-09     Document Type: Article

References (36)

1. Chupakhin, O. N., V. L. Rusinov, E. N. Ulomsky, V. N. Charushin, A. Y. Petrov, and O. N. Kiselev. March 2007. 2-Methylthio-6-nitro-1,2,4-triazolo[5,1- C]-1,2,4-triazine-7(4H)-one. Sodium salt dihydrate possessing antiviral activity. Russian patent RU 2,294,936.
2. Fuyuno, I. 2007. Tamiflu side effects come under scrutiny. Nature 446:358-359.
3. Glezen, W. P. 1996. Emerging infections: pandemic influenza. Epidemiol. Rev. 18:64-76.
4. Hama, R. 2007. Fifty sudden deaths may be related to central suppression. BMJ 335:59.
5. Hay, A. 1996. Amantadine and rimantadine - mechanisms, p. 44-58. In D. Richman (ed.), Antiviral drug resistance. John Wiley and Sons Ltd., Chichester, United Kingdom.
6. Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:3021-3024.
7. Hayden, F. 2004. Annex 5: considerations for the use of antivirals during an influenza pandemic, p.5-1-5-18. In WHO guidelines on the use of vaccines and antivirals during influenza pandemics. World Health Organization, Geneva, Switzerland. http://www.wpro.who.int/internet/resources.ashx/CSR/Publications/ 11-29-01-A.pdf.
8. Hayden, F. G., and A. J. Hay. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176:119-130.
9. Jing, X., C. Ma. Y. Ohigashi, F. A. Oliveira, T. S. Jardetsky, L. H. Pinto, and R. A. Lamb. 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 105:10967-10972.
10. Johnston, S. L. 2002. Anti-influenza therapies. Virus Res. 82:147-152.
11. Khandazhinskaya, A. L., D. V. Yanvarev, M. V. Jasko, A. V. Shipitsin, V. A. Khalizev, S. I. Shram, Y. S. Skoblov, E. A. Shirokova, and M. K. Kukhanova. 2009. 5́ -aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. Drug Metab. Dispos. 37:494-501.
12. Klenk, H. D., and R. Rott. 1988. The molecular biology of influenza virus pathogenicity. Adv. Virus Res. 34:247-280.
13. Kuznetsov, O. K., and O. I. Kiselev. 2003. Influenza viruses with pandemic potential and measures to prevent their emergence: facts, hypothesis. Med. Acad. J. 2:112-121.
14. Laver, W. G., N. Bischofberger, and R. G. Webster. 1999. Disarming flu viruses. Sci. Am. 280:78-87.
15. Leneva, I. A., N. Roberts, E. A. Govorkova, O. G. Goloubeva, and R. G. Webster. 2000. The neuraminidase inhibitor GS 4104 (oseltamir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/ 1074/99 (H9N2) influenza viruses. Antiviral Res. 48:101-115.
16. Liu, C., M. C. Eichelberger, R. W. Compans, and G. M. Air. 1995. Influenza type A virus neuraminidase does not play a role in virus entry, replication, assembly, or budding. J. Virol. 69:1099-1106.
17. Mackay, W. G., A. M. van Loon, M. Niedrig, A. Meijer, B. Lina, and H. G. Niesters. 2008. Molecular detection and typing of influenza viruses: are we ready for an influenza pandemic? J. Clin. Virol. 42:194-197.
18. Maxwell, S. R. 2007. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334:1232-1233.
19. Monto, A. S. 2008. Antivirals and influenza: frequency of resistance. Pediatr. Infect. Dis. J. 27(10 Suppl.):S110-S112.
20. Moscona, A. 2005. Neuraminidase inhibitors for influenza. New Engl. J. Med. 353:1363-1373.
21. Mounts, A. W., H. Kwong, H. S. Izurieta, Y. Ho, T. Au, M. Lee, C. Buxton Bridges, S. W. Williams, K. H. Mak, J. M. Katz, W. W. Thompson, N. J. Cox, and K. Fukuda. 1999. Case-control study of risk factors for avian influenza A (H5N1) diseases, Hong Kong, 1997. J. Infect. Dis. 180(Suppl. 2):505-508.
22. National Institutes of Health. 1986. Guide for the care and use of laboratory animals. NIH publication 86/609/EEC. National Institutes of Health, Bethesda, MD.
23. Osterholm, M. T. 2005. Preparing for the next pandemic. New Engl. J. Med. 352:1839-1842.
24. Pappaioanou, M. 2009. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic? Comp. Immunol. Microbiol. Infect. Dis. 32:287-300.
25. 2 is a potent inhibitor of influenza A virus replication. Antimicrob. Agents Chemother. 44:200-204.
26. Pielak, R. M., J. R. Schnell, and J. J. Chou. 2009. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. U. S. A. 106:7379-7384.
27. Reed, L., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
28. Rossignol, J. F., S. La Frazia, L. Chiappa, A. Ciucci, and M. G. Santoro. 28 July 2009. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. [Epub ahead of print.] doi:10.1074/jbc.M109.029470.
29. Schnell, J. R., and J. J. Chou. 2008. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451:591-595.
30. Schwartz, M., M. Patel, Z. Kazzi, and B. Morgan. 2008. Cardiotoxicity after massive amantadine overdose. J. Med. Toxicol. 4:173-179.
31. Skoblov, Y., I. Karpenko, E. Shirokova, K. Popov, V. Andronova, G. Galegov, and M. Kukhanova. 2004. Intracellular metabolism and pharmacokinetics of 5′-hydrogen phosphonate of 3′-azido-2′,3′- dideoxythymidine, a prodrug of 3′-azido-2′,3′- dideoxythymidine. Antiviral Res. 63:107-113.
32. Smith, E. J. 2008. Amantadine-induced psychosis in a young healthy patient. Am. J. Psychiatr. 165:1613.
33. Ulomskii, E. N., E. V. Tsoi, V. L. Rusinov, O. N. Chupakhin, G. L. Kalb, and I. M. Sosonkin. 1992. Reduction of nitro derivatives of azolo[5,1-c][1,2,4] triazines. Khimiya Geterotsiklicheskikh Soedinenii 5:674-677. (In Russian.)
34. Veeraraghavan, N., M. W. Kiritikar, and T. T. Sreevalsan. 1961. Studies on the cultivation of influenza virus in vitro. Bull. W. H. O. 24:711-722.
35. Wang, C. K., L. H. Takeuchi, and R. A. Lamb. 1993. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67:5585-5594.
36. Ward, P., I. Small, J. Smith, and R. Dutkowski. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1):i5-i21.